Novel monoclonal antibody shows promise against moderate to severe AD
A phase I, single-centre, open-label study has found that repeated intravenous infusions of KHK4083, an investigational human monoclonal antibody, is sufficiently safe and clinically effective for the treatment of moderate to severe atopic dermatitis (AD).